Opioid use and ventilator-associated pneumonia

Current Respiratory Medicine Reviews

Volumn 6, Issue 1, 2010, Pages 72-77

  Makris, Demosthenes ^a,b   Lubret, Rémy ^a   Nseir, Saad ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Immunomodulation; Opioids; Ventilator associated pneumonia

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; MIDAZOLAM; MORPHINE; NITRIC OXIDE; OPIATE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 9;

ANTIBODY PRODUCING CELL; ARTIFICIAL VENTILATION; B LYMPHOCYTE ACTIVATION; BACTERIAL VIRULENCE; CONSTIPATION; CYTOKINE PRODUCTION; DROWSINESS; DRUG USE; GASTROINTESTINAL MOTILITY; HOST RESISTANCE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION RISK; INTENSIVE CARE; MIOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING; XEROSTOMIA;

EID: 77950394688     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339810790820449     Document Type: Review

References (71)

1. Garrouste-Orgeras M, Timsit JF, Soufir L, et al. Impact of adverse events on outcomes in intensive care unit patients. Crit Care Med 2008; 36: 2041-2047
2. Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005; 33: 2184-2193
3. Melsen WG, Rovers MM, Bonten MJ. Ventilator-associated pneumonia and mortality: a systematic review of observational studies. Crit Care Med 2009; 37:2709-2718
4. Sessler CN, Wilhelm W. Analgesia and sedation in the intensive care unit: an overview of the issues. Crit Care 2008; 12(Suppl 3): S1.
5. Sessler CN, Varney K. Patient-focused sedation and analgesia in the ICU. Chest 2008; 133: 552-565
6. Arroliga A, Frutos-Vivar F, Hall J, et al. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005; 128: 496-506.
7. rd ed. New York, NY: Oxford University Press 2004; pp. 229-239
8. Donahoe RM. Drug abuse and AIDS: causes for the connection. NIDA Res Monogr 1990; 96: 181-191
9. Bryant HU, Bernton EW, Holaday JW. Morphine pellet-induced immunomodulation in mice: temporal relationships. J Pharmacol Exp Ther 1988; 245: 913-920
10. Shavit Y, Terman GW, Lewis JW, et al. Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance. Brain Res 1986; 372: 382-385
11. Avila AH, Alonzo NC, Bayer BM. Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine. J Neuroimmunol 2004; 147: 109-113
12. Pacifici R, Di Carlo S, Bacosi A, et al. Macrophage functions in drugs of abuse-treated mice. Int J Immunopharmacol 1993; 15: 711-716
13. Risdahl JM, Peterson PK, Chao CC, et al. Effects of morphine dependence on the pathogenesis of swine herpesvirus infection. J Infect Dis 1993; 167: 1281-1287
14. West JP, Lysle DT, Dykstra LA. Tolerance development to morphine-induced alterations of immune status. Drug Alcohol Depend 1997; 46: 147-157
15. Bornstain C, Azoulay E, De Lassence A. et al. Sedation, sucralfate, and antibiotic use are potential means for protection against early-onset ventilator-associated pneumonia. Clin Infect Dis 2004; 38: 1401-1408
16. Metheny NA, Clouse RE, Chang YH, et al. Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med 2006; 34: 1007-1015
17. Georges H, Leroy O, Guery B, et al. Predisposing factors for nosocomial pneumonia in patients receiving mechanical ventilation and requiring tracheotomy. Chest 2000; 118: 767-774
18. Schwacha MG, McGwin G, Jr., Hutchinson CB, et al. The contribution of opiate analgesics to the development of infectious complications in burn patients. Am J Surg 2006; 192: 82-86
19. Nseir S, Hoel J, Grailles G, et al. Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study. Crit Care 2009; 13: R60-
20. Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-1477
21. Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114: 541-548
22. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129: 433-440
23. Akca O, Koltka K, Uzel S, et al. Risk factors for early-onset, ventilator-associated pneumonia in critical care patients: selected multiresistant versus nonresistant bacteria. Anesthesiology 2000; 93: 638-645
24. Nseir S, Di Pompeo C, Jozefowicz E, et al. Relationship between tracheotomy and ventilator-associated pneumonia: a case control study. Eur Respir J 2007; 30: 314-320
25. Alp E, Guven M, Yildiz O, et al. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob 2004; 3: 17.
26. Arya V, Ramji S. Midazolam sedation in mechanically ventilated newborns: a double blind randomized placebo controlled trial. Indian Pediatr 2001; 38: 967-972
27. Craven DE. Preventing ventilator-associated pneumonia in adults: sowing seeds of change. Chest 2006; 130: 251-260
28. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 2005; 50: 725-739
29. Kolbel CB, Rippel K, Klar H, et al. Esophageal motility disorders in critically ill patients: a 24-hour manometric study. Intensive Care Med 2000; 26: 1421-1427
30. Fruhwald S, Holzer P, Metzler H. Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact. Intensive Care Med 2007; 33: 36-44.
31. Sternini C, Patierno S, Selmer IS, et al. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004; 16(Suppl 2): 3-16.
32. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990; 5: 362-367
33. van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, et al. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med 2007; 35: 2726-2731
34. Husebye E. Gastrointestinal motility disorders and bacterial overgrowth. J Intern Med 1995; 237: 419-427
35. Haglund U. Systemic mediators released from the gut in critical illness. Crit Care Med 1993; 21: S15-S18.
36. Ritz MA, Fraser R, Tam W, et al. Impacts and patterns of disturbed gastrointestinal function in critically ill patients. Am J Gastroenterol 2000; 95: 3044-3052
37. Lysle DT, Coussons ME, Watts VJ, et al. Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J Pharmacol Exp Ther 1993; 265: 1071-1078
38. Gomez-Flores R, Weber RJ. Inhibition of interleukin-2 production and downregulation of IL-2 and transferrin receptors on rat splenic lymphocytes following PAG morphine administration: a role in natural killer and T cell suppression. J Interferon Cytokine Res 1999; 19: 625-630
39. Nelson CJ, How T, Lysle DT. Enhancement of the contact hypersensitivity reaction by acute morphine administration at the elicitation phase. Clin Immunol 1999; 93:176-183
40. Singh PP, Singal P. Morphine-induced neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines and nitric oxide. J Neuroimmune Pharmacol 2007; 2: 338-351
41. Jamali A, Bamdad T, Soleimanjahi H, et al. Acute morphine administration reduces white blood cells' capability to induce innate resistance against HSV-1 infection in BALB/c mice. Neuroimmunomodulation 2007; 14: 16-23.
42. Li Y, Ye L, Peng JS, et al. Morphine inhibits intrahepatic interferon- alpha expression and enhances complete hepatitis C virus replication. J Infect Dis 2007; 196: 719-730
43. Brand JM, Frohn C, Luhm J, et al. Early alterations in the number of circulating lymphocyte subpopulations and enhanced proinflammatory immune response during opioid-based general anesthesia. Shock 2003; 20: 213-217
44. Shavit Y, Lewis JW, Terman GW, et al. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 1984; 223: 188-190
45. Bussiere JL, Adler MW, Rogers TJ, et al. Differential effects of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol Immunotoxicol 1992; 14: 657-673
46. Tubaro E, Borelli G, Croce C, et al. Effect of morphine on resistance to infection. J Infect Dis 1983; 148: 656-666
47. Rojavin M, Szabo I, Bussiere JL, et al. Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci 1993; 53: 997-1006.
48. Malik AA, Radhakrishnan N, Reddy K, et al. Morphine-induced macrophage apoptosis modulates migration of macrophages: use of in vitro model of urinary tract infection. J Endourol 2002; 16: 605-610
49. Bayer BM, Daussin S, Hernandez M, et al. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 1990; 29: 369-374
50. Bayer BM, Gastonguay MR, Hernandez MC. Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility. Immunopharmacology 1992; 23: 117-124
51. Xu J, Li PF, Liu XH, et al. Morphine aggravates the apoptosis of simian immunodeficiency virus infected CEM x174 cells in the prolonged culture in vitro. Int Immunopharmacol 2004; 4: 1805-1816
52. Carr DJ. The role of endogenous opioids and their receptors in the immune system. Proc Soc Exp Biol Med 1991; 198: 710-720
53. Caroleo MC, Arbitrio M, Melchiorri D, et al. A reappraisal of the role of the various opioid receptor subtypes in cell-mediated immunity. Neuroimmunomodulation 1994; 1: 141-147
54. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 2000; 7: 719-723
55. McCarthy L, Wetzel M, Sliker JK, et al. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62: 111-123
56. Fecho K, Maslonek KA, Dykstra LA, et al. Alterations of immune status induced by the sympathetic nervous system: immunomodulatory effects of DMPP alone and in combination with morphine. Brain Behav Immun 1993; 7: 253-270
57. Fecho K, Dykstra LA, Lysle DT. Evidence for beta adrenergic receptor involvement in the immunomodulatory effects of morphine. J Pharmacol Exp Ther 1993; 265: 1079-1087
58. Hernandez MC, Flores LR, Bayer BM. Immunosuppression by morphine is mediated by central pathways. J Pharmacol Exp Ther 1993; 267: 1336-1341
59. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J Neuroimmunol 1998; 83: 19-28.
60. Saurer TB, Ijames SG, Lysle DT. Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity. J Neuroimmunol 2006; 177: 18-26.
61. Zaborina O, Lepine F, Xiao G, et al. Dynorphin activates quorum sensing quinolone signaling in Pseudomonas aeruginosa. PLoS Pathog 2007; 3: e35.
62. Wang J, Barke RA, Charboneau R, et al. Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling. J Immunol 2008; 180: 3594-3600
63. Kishioka S, Nishida S, Fukunaga Y, et al. Quantitative properties of plasma corticosterone elevation induced by naloxone-precipitated withdrawal in morphine-dependent rats. Jpn J Pharmacol 1994; 66: 257-263
64. West JP, Dykstra LA, Lysle DT. Immunomodulatory effects of morphine withdrawal in the rat are time dependent and reversible by clonidine. Psychopharmacology (Berl) 1999; 146: 320-327
65. Rahim RT, Adler MW, Meissler JJ, Jr. et al. Abrupt or precipitated withdrawal from morphine induces immunosuppression. J Neuroimmunol 2002; 127: 88-95.
66. Feng P, Meissler JJ, Jr., Adler MW, et al. Morphine withdrawal sensitizes mice to lipopolysaccharide: elevated TNF-alpha and nitric oxide with decreased IL-12. J Neuroimmunol 2005; 164: 57-65.
67. Feng P, Wilson QM, Meissler JJ, Jr. et al. Increased sensitivity to Salmonella enterica serovar Typhimurium infection in mice undergoing withdrawal from morphine is associated with suppression of interleukin-12. Infect Immun 2005; 73: 7953-7959
68. Feng P, Truant AL, Meissler JJ, Jr. et al. Morphine withdrawal lowers host defense to enteric bacteria: spontaneous sepsis and increased sensitivity to oral Salmonella enterica serovar Typhimurium infection. Infect Immun 2006; 74: 5221-5226
69. von D, V, Luetz A, Haas A, et al. Effects of remifentanil and fentanyl on the cell-mediated immune response in patients undergoing elective coronary artery bypass graft surgery. J Int Med Res 2008; 36: 1235-1247
70. Muellejans B, Matthey T, Scholpp J, et al. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial. Crit Care 2006; 10: R91.
71. Rozendaal FW, Spronk PE, Snellen FF, et al. Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands. Intensive Care Med 2009; 35: 291-298